Named on one round in the feed.
Since 2025-04-02
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Atsena Therapeutics Atsena Therapeutics develops gene therapies for inherited retinal diseases, targeting conditions like X-linked retinoschisis and Leber congenital amaurosis. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $150M | 2025-04-02 | [ PART ] |